Stereotactic radiosurgery for treatment of radiation-induced meningiomas: a multiinstitutional study.

Gamma Knife local control oncology progression-free survival radiation-induced meningioma safety stereotactic radiosurgery

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
01 Jan 2021
Historique:
received: 29 05 2020
accepted: 14 07 2020
medline: 2 1 2021
pubmed: 2 1 2021
entrez: 1 1 2021
Statut: epublish

Résumé

Radiation-induced meningiomas (RIMs) are associated with aggressive clinical behavior. Stereotactic radiosurgery (SRS) is sometimes considered for selected RIMs. The authors investigated the effectiveness and safety of SRS for the management of RIMs. From 12 institutions participating in the International Radiosurgery Research Foundation, the authors pooled patients who had prior cranial irradiation and were subsequently clinically diagnosed with WHO grade I meningiomas that were managed with SRS. Fifty-two patients underwent 60 SRS procedures for histologically confirmed or radiologically suspected WHO grade I RIMs. The median ages at initial cranial radiation therapy and SRS for RIM were 5.5 years and 39 years, respectively. The most common reasons for cranial radiation therapy were leukemia (21%) and medulloblastoma (17%). There were 39 multiple RIMs (35%), the mean target volume was 8.61 ± 7.80 cm3, and the median prescription dose was 14 Gy. The median imaging follow-up duration was 48 months (range 4-195 months). RIM progressed in 9 patients (17%) at a median duration of 30 months (range 3-45 months) after SRS. Progression-free survival at 5 years post-SRS was 83%. Treatment volume ≥ 5 cm3 predicted progression (HR 8.226, 95% CI 1.028-65.857, p = 0.047). Seven patients (14%) developed new neurological symptoms or experienced SRS-related complications or T2 signal change from 1 to 72 months after SRS. SRS is associated with durable local control of RIMs in the majority of patients and has an acceptable safety profile. SRS can be considered for patients and tumors that are deemed suboptimal, poor surgical candidates, and those whose tumor again progresses after removal.

Identifiants

pubmed: 33385995
doi: 10.3171/2020.7.JNS202064
pii: 2020.7.JNS202064
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

862-870

Auteurs

Adomas Bunevicius (A)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Mohand Suleiman (M)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Samir Patel (S)

2Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.

Roberto Martínez Álvarez (R)

3Gamma Knife Radiosurgery, Hospital Ruber Internacional, Madrid, Spain.

Nuria E Martinez Moreno (NE)

3Gamma Knife Radiosurgery, Hospital Ruber Internacional, Madrid, Spain.

Roman Liscak (R)

4Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.

Jaromir Hanuska (J)

4Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.

Anne-Marie Langlois (AM)

5Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.

David Mathieu (D)

5Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.

Christine Mau (C)

6Penn State Health, Hershey Medical Center, Hershey, Pennsylvania.

Catherine Caldwell (C)

6Penn State Health, Hershey Medical Center, Hershey, Pennsylvania.

Leonard C Tuanquin (LC)

6Penn State Health, Hershey Medical Center, Hershey, Pennsylvania.

Brad E Zacharia (BE)

6Penn State Health, Hershey Medical Center, Hershey, Pennsylvania.

James McInerney (J)

6Penn State Health, Hershey Medical Center, Hershey, Pennsylvania.

Cheng-Chia Lee (CC)

7Neurological Institute, Taipei Veterans General Hospital, and National Yang-Ming University, Taipei, Taiwan.

Huai-Che Yang (HC)

7Neurological Institute, Taipei Veterans General Hospital, and National Yang-Ming University, Taipei, Taiwan.

Jennifer L Peterson (JL)

8Radiation Oncology, Mayo Clinic, Jacksonville, Florida.

Daniel M Trifiletti (DM)

8Radiation Oncology, Mayo Clinic, Jacksonville, Florida.

Akiyoshi Ogino (A)

9Department of Neurologic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Hideyuki Kano (H)

9Department of Neurologic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Ronald E Warnick (RE)

10Jewish Hospital, Mayfield Clinic, Cincinnati, Ohio.

Anissa Saylany (A)

11Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania; and.

Love Y Buch (LY)

11Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania; and.

John Y K Lee (JYK)

11Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania; and.

Ben A Strickland (BA)

12University of Southern California, Los Angeles, California.

Gabriel Zada (G)

12University of Southern California, Los Angeles, California.

Eric L Chang (EL)

12University of Southern California, Los Angeles, California.

L Dade Lunsford (LD)

9Department of Neurologic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Jason Sheehan (J)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Classifications MeSH